Breast cancer biomarker study
Part of Cancer, Skin clinical trials.
This study looks for markers in your blood or tissue that might help predict how breast cancer will respond to treatment. It aims to improve future care by understanding these markers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with breast cancer.
- You are being treated at Saint-Louis Hospital in Paris.
- You agree to participate and have not said no to research.
- You are covered by the French national health system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for new lab “markers” that may help predict how breast cancer is likely to behave over time. Your tumor or health information may be used to find factors that can guide doctors’ predictions.
This study looks at breast cancer samples taken by biopsy to see how tissue “molecular markers” relate to how you respond to therapy and how the cancer behaves. It may help researchers better match future treatments to the biology of your tumor.
This trial looks at blood samples to measure substances that may reflect cancer (tumor markers). It may help doctors understand cancer better and improve future monitoring, as long as you can safely and regularly take part.
This study uses a special type of mammogram with contrast dye to see if it can predict how well breast cancer responds to chemotherapy before surgery. It's for people with HER2-positive or triple-negative breast cancer.
This study looks at how your immune system changes while you receive standard breast cancer treatments. The researchers measure immune-related signals during your treatment to better understand what may be happening in triple-negative or certain hormone-receptor breast cancers.
This study looks at why some breast cancers stop responding to treatment. It involves taking a small sample of your tumor (biopsy) and blood to understand resistance. If you have HER2-positive or triple-negative breast cancer that is growing despite treatment, you may be able to join.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.